These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. Komatsubara KM; Carvajal RD Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938 [TBL] [Abstract][Full Text] [Related]
5. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma. Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489 [TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab as first-line treatment for metastatic uveal melanoma. Rossi E; Pagliara MM; Orteschi D; Dosa T; Sammarco MG; Caputo CG; Petrone G; Rindi G; Zollino M; Blasi MA; Cassano A; Bria E; Tortora G; Schinzari G Cancer Immunol Immunother; 2019 Jul; 68(7):1179-1185. PubMed ID: 31175402 [TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option? Bender C; Enk A; Gutzmer R; Hassel JC Cancer Med; 2017 Jul; 6(7):1581-1586. PubMed ID: 28639409 [TBL] [Abstract][Full Text] [Related]
8. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704 [TBL] [Abstract][Full Text] [Related]
9. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830 [TBL] [Abstract][Full Text] [Related]
10. Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. Smithy JW; Moore LM; Pelekanou V; Rehman J; Gaule P; Wong PF; Neumeister VM; Sznol M; Kluger HM; Rimm DL J Immunother Cancer; 2017; 5():25. PubMed ID: 28331615 [TBL] [Abstract][Full Text] [Related]
11. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333 [TBL] [Abstract][Full Text] [Related]
12. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. Afzal MZ; Mabaera R; Shirai K J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557 [TBL] [Abstract][Full Text] [Related]
13. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657 [TBL] [Abstract][Full Text] [Related]
14. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057 [TBL] [Abstract][Full Text] [Related]
15. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Maio M; Danielli R; Chiarion-Sileni V; Pigozzo J; Parmiani G; Ridolfi R; De Rosa F; Del Vecchio M; Di Guardo L; Queirolo P; Picasso V; Marchetti P; De Galitiis F; Mandalà M; Guida M; Simeone E; Ascierto PA Ann Oncol; 2013 Nov; 24(11):2911-5. PubMed ID: 24067719 [TBL] [Abstract][Full Text] [Related]
17. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. Cybulska-Stopa B; Rogala P; Czarnecka AM; Ługowska I; Teterycz P; Galus Ł; Rajczykowski M; Dawidowska A; Piejko K; Suwiński R; Mackiewicz J; Rutkowski P Adv Med Sci; 2020 Sep; 65(2):316-323. PubMed ID: 32554313 [TBL] [Abstract][Full Text] [Related]
19. Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure. Klee G; Kurzhals J; Hagelstein V; Zillikens D; Recke A; Langan EA; Terheyden P Melanoma Res; 2021 Oct; 31(5):464-471. PubMed ID: 34284462 [TBL] [Abstract][Full Text] [Related]
20. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174 [No Abstract] [Full Text] [Related] [Next] [New Search]